tbuckley/cabot-search huggingface dataset:
Early and Effective Immune-Recovery by Gene-Engineered Lymphocytes after Haploidentical Transplantation for Leukemia Abate Late Transplant Mortality
Authors: Maria Teresa Lupo Stanghellini, Fabio Ciceri, Chiara Bonini, Attilio Bondanza, Catia Traversari, Monica Salomoni, Lucia Turchetto, Scialini Colombi, Massimo Bernardi, Jacopo Peccatori, Alessandra Pescarollo, Paolo Servida, Zulma Magnani, Serena Kimi Perna, Veronica Valtolina, Fulvio Crippa, Luciano Callegaro, Elena Spoldi, Roberto Crocchiolo, Katharina Fleischhauer, Maurilio Ponzoni, Luca Vago, Armando Santoro, Elisabetta Todisco, Jane Apperley, Eduardo Olavarria, Shimon Slavin, Eva Maria Weissinger, Bernd Hertenstein, Michael Stadler, Evangelia Yannaki, Athanasios Fassas, Achilles Anagnostopoulos, Corrado Gallo Stampino, Marco Bregni, Paolo Bruzzi, Claudio Bordignon
Journal: Blood (2008)
Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas (PETAL trial): Correlation between Clinical Variables and PET Parameters.
Authors: Andreas Hüttmann, Stefan Müller, Andreas Bockisch, Rolf Mesters, Frank Kroschinsky, Gabriele Prange-Krex, Henrike Thomssen, Aristoteles Giagounidis, Ulrich Duehrsen
Journal: Blood (2009)
Leukemogenic WT1 Mutations Increase Proliferation by Accelerating Cell Entry Into S-Phase, and Synergize with FLT3/ITD Mutations to Enhance These Aberrant Cell Cycle Effects
Authors: Colleen E. Annesley, Rachel E. Rau, Gregory McCarty, Daniel Magoon, Edward Allan R. Sison, David Loeb, Patrick A. Brown
Journal: Blood (2011)
Efficacy of Baxter’s Longer Acting rFVIII (BAX 855) in Mouse Models of Hemophilia A
Authors: Alexandra Schiviz, Eder Barbara, John-Philip Lawo, Hartmut J. Ehrlich, Friedrich Scheiflinger, Peter L Turecek, Hans Peter Schwarz, Eva-Maria Muchitsch, Werner Hoellriegl
Journal: Blood (2011)
Don’t forget the humanitarian paradox at home
Authors: Andrew Moscrop
Journal: BMJ (2016)

van Tulleken talks of the humanitarian paradox,1 but let’s not overstate it—the efforts of healthcare providers do not always exacerbate the problem of refugee camps. The basic healthcare provided in refugee camps in Europe is unlikely to have attracted many of the 1.2 million people who arrived in 2015, most fleeing conflict zones.2 Nor …
Characterization of Patients with Multiple Myeloma and t(4;14) Detected by Fluorescence In Situ Hybridization.
Authors: Rosa Collado, Jose A. Hueso, Miriam Romaguera, Carmen Mora, Aurelio Lopez, Carmen Benet, Victoria Amigo, Rosa Ferrer, Isabel Navarro, Angeles Ruiz, Jose Martinez, Alejandro Pacios, Maite Orero, Amparo Miguel-Sosa, Carbonell Felix
Journal: Blood (2005)
Hematopoietic miRNAs Expression in Myelodysplastic Syndromes.
Authors: Aina Pons, Benet Nomdedeu, Alfons Navarro, Anna Gaya, Silvia Pairet, Miquel Granell, Sandra Valera, Bernat Gel, Emili Montserrat, Mariano Monzo
Journal: Blood (2007)
HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens,
Authors: Pleun Hombrink, Chopie Hassan, Michel G.D. Kester, Cornelis A.M. van Bergen, J.H.F. Falkenburg, Peter A. van Veelen, Mirjam H.M. Heemskerk
Journal: Blood (2011)
Fractional Flow Reserve Derived From Routine Coronary Angiograms
Authors: Ran Kornowski, Ifat Lavi, Mariano Pellicano, Panagiotis Xaplanteris, Hana Vaknin-Assa, Abid Assali, Orna Valtzer, Yonit Lotringer, Bernard De Bruyne
Journal: Journal of the American College of Cardiology (2016)
A Combination of Rituxan, Cyclophosphamide and Dexamethasone (RCD) Results in Long-Lasting Responses in Autoimmune Anemia and Thrombocytopenia in CLL Patients: A Single Institution Study.
Authors: Matthew S. Kaufman, Yehuda Z. Lebowicz, Nancy Driscoll, Christina Johnson, Dale Janson, Angelica Caramanica, Rajasree Roy, Neetu Radhakrishnan, Dhaval Mehta, Mark Hoffman, Dilip Patel, Nina Kohn, Kanti R. Rai
Journal: Blood (2006)
SAT0537 Sensitivity and Specificity of Ultrasound Score for The Diagnosis of Gout: Table 1.
Authors: M.M. Basaric, G. Radunovic, N. Damjanov, M. Perovic-Radak
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To determine sensitivity and specificity of ultrasound score (US-score) for the diagnosis of gout, by ultrasound (US) examination, of the first metatarsophalangeal (MTP1) joint. <h3>Methods</h3> A groups of 60 patients (pts) with primary gout of the MTP1 joints were examined. Diagnosis was established by EULAR criteria for diagnosis of gout. In the group of gouty patients, only symptomatic MTP1 joints (n=83 joints) were examined by US. US findings of 60 pts (83 joints) were compared with US findings of 35 healthy controls (n=70 joints). Both groups were comparable according to age, sex and BMI. US examination was done by 18 MHz probe. The existence of: "double contour", tophi, "starry sky" and/or "snowstorm" signs, hyperechoic cloudy areas (HCA), joint effusion, bone erosions, power Doppler signal and synovial hypertrophy were assessed. After determining the sensitivity and specificity of all these US signs individually, they were qualitative scored as 0 (absent) or 1 (present) and scored as follows: US8-US0-score "0–8", whereby "0" means that none of the characteristics are present, and "8" means that all listed US findigns are present. <h3>Results</h3> The area under the ROC curve for total US8-score was 0.901 ± 0.025. The diagnostic sensitivity and specificity of US8-score in the MTP1 joint was 79,5% and 85,7% respectively, if value 1,50 was determined as cut-off (table 1). The synovial hypertrophy was excluded from the equation and US7- score was calculated. According to our findings US7-score in the MTP1 joint had the best sensitivity and high specificity for diagnosis gout, because the area under the ROC curve was 0.924 ± 0.021. The sensitivity of the US7-score was 82.9% and specificity 91.7%, if value 1.50 was determined as cut-off (table 1). <h3>Conclusions</h3> US7 score ("double contour", tophi, "starry sky" and/or "snowstorm" signs, HCA, joint effusion, bone erosions and power Doppler signal) had highest area under the ROC curve (0,924), and highest sensitivity (82,9%) and specificity (91,7%) for the diagnosis of gout. <h3>References</h3> Gutierrez M, Smith W, Thiele R, et al. Defining elementary ultrasound lesions in gout. preliminary results of delphi consensus and web-exercise reliability. Ann Rheum Dis 2014; 73(Suppl2). Ottaviani S, Bardin T, Richette P. Usefulness of ultrasonographyfor gout. Joint Bone Spine 2012; 79: 441–445 Wakefield RJ, Balint PV, Szkudlarek M, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005; 32: 2485–2487. <h3>Disclosure of Interest</h3> None declared
Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Antigen Levels and TAFI Gene Polymorphisms in Patients with Budd-Chiari Syndrome and Portal Vein Thrombosis.
Authors: Emile L.E. de Bruijne, Sarwa D. Murad, Moniek P. de Maat, Elizabeth B. Haagsma, Bart van Hoek, Frits R. Rosendaal, Harry L.A. Janssen, Frank W.G. Leebeek
Journal: Blood (2004)
Prognostic Significance of Central Nervous System (CNS) Status of Children with Acute Lymphoblastic Leukemia (ALL) Treated without Cranial Irradiation: Results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group Study 58951
Authors: Nicolas Sirvent, Stefan Suciu, Yves Benoit, Yves Bertrand, Brigitte Nelken, Alain Robert, Anne Uyttebroeck, Patrick Lutz, Alina Ferster, Karima Yacouben, Lucilia Norton, Geneviève Margueritte, Martine Munzer, Dominique Plantaz, Frédéric Millot, Patrick Boutard, Pierre Philippet, Claire Hoyoux, Liliana Baila, Jacques Otten
Journal: Blood (2008)
De Novo t(14;18) Diffuse Large B-Cell Lymphoma Is Characterized by a Germinal Center B Cell-Like Phenotype and Acquisition of Glycosylation Sites by Somatic Mutation in Immunoglobulin VH Genes.
Authors: Fabrice Jardin, Francoise Parmentier, Surinder S. Sahota, Jean Michel Picquenot, Philippe Ruminy, Gerard Buchonnet, Herve Tilly, Christian Bastard
Journal: Blood (2004)
A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study.
Authors: Yung-Jue Bang
Journal: Journal of Clinical Oncology (2013)

11 Background: The use of trastuzumab has been established as the standard first-line treatment of HER2 positive (+) AGC. However, the role of anti-HER2 agents in the second-line treatment of HER2+ AGC has not been clearly established yet. TyTAN is the first randomized study to compare the efficacy and safety of adding lapatinib (L) to paclitaxel (P) vs P alone in the second-line treatment of HER2+ AGC. Methods: Eligibility required patients (pts) with AGC, amplification of HER2 by fluorescence in situ hybridization (FISH), and one prior regimen containing fluoropyrimidines and/or cisplatin. Pts were randomized 1:1 to L (1500mg QD) and P (80mg/m 2 , Day 1, 8, 15 q4w) or P alone. The treatments were given until disease progression or unacceptable toxicity. Stratification variables were prior trastuzumab treatment and gastrectomy status. Primary endpoint was overall survival (OS). Results: From March 2008 to June 2011, 1923 pts were screened and 430 pts were HER2+ AGC. 261 out of 430 pts were enrolled. All pts were from Asian countries: Japan (100), China (95), Korea (46), and Taiwan (20). Median OS was 11.0 months for L+P and 8.9 months for P alone in the intent-to-treat (ITT) population (HR 0.84; p=0.2088). In a pre-planned subgroup analysis, median OS in HER2 immunohistochemistry (IHC) 3+ subgroup was 14.0 months for L+P and 7.6 months for P alone (HR 0.59; p=0.0176). The endpoints in efficacy and AEs of special interest for L+P are summarized below (Table). Conclusions: Although OS was prolonged in L+P arm by 2 months, the difference was not statistically significant. HER2 IHC 3+ subgroup demonstrated statistically significant prolongation of OS by adding L. Clinical trial information: NCT00486954. [Table: see text]
Survival Outcomes of Leukemias and Myelodysplastic Syndromes Occurring As Second Cancers in the United States: A SEER Registry-Based Population Analysis
Authors: Surbhi Sidana, Paul Elson, Aaron T. Gerds, Hetty E. Carraway, Anjali S. Advani, Yogen Saunthararajah, Jaroslaw P. Maciejewski, Matt Kalaycio, Mikkael A. Sekeres, Sudipto Mukherjee
Journal: Blood (2015)
SAT0062 Test for Serum Progranulin Autoantibodies Can Reduce The Seronegative Status in Rheumatoid Arthritis by One Third
Authors: G. Assmann, S. Zinke, M. Gerling, N. Fadle, D. Preuss, M. Pfreundschuh, L. Thurner
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Progranulin autoantibodies (PGRNabs) have been previously described in sera of patients with different autoimmune diseases such as ANCA associated vasculitis, large vessel vaskulitis, Crohn9s disease, polyarthritis including psoriatic arthritis and rheumatoid arthritis, whereas healthy controls and patients with different non-rheumatological disorders have shown a prevalence less than 1% [Ref.]. At primary diagnosis of rheumatoid arthritis as well as during the course of diseases at least 25% of RA patients have never developed serum RF or ACPA. Here we conducted a study on RA patients who were tested for RF, ACPA, and PRGNabs to evaluate the prevalence of serostatus in RA. <h3>Objectives</h3> Prevalence of serum PRGNabs in RA with stratification into seropositive RA patients with the proof of serum RF and/or ACPA and seronegative RA patients. <h3>Methods</h3> From Nov 2011 till Dec 2013 sera of 271 RA patients were collected and analyized for RF-IgM, ACPA-IgG, and PGRNabs with ELISA (as previously published) using a retrospective, blinded, non-randomized study design. All patients were on treatment with conventional DMARDS (n=165) or TNF inhibitors (n=106). All patients fullfilled the ACR criteria from 1987 and the revised diagnostic EULAR/ACR criteria from 2011. RA patients characteristics concerning age, gender, treatment history, radiological joint imaging, and duration of disease were availiable. <h3>Results</h3> The overall prevalence of PGRNabs in RA patients was 29,2%. 222 RA patients were seropositive for RF and/or ACPA, 49 RA patients were seronegative. Testing for PRGNabs resulted in significantly higher prevalence of PRGNabs in RF- and ACPA-seronegative RA patients compared to RA patients with seropositivity in at least one of serummarkers RF or ACPA (27.5% versus 36.7%, p=0.021, Chi2 test) [Figure]. The prevalence of PRGNabs in RF-positive RA patients were significant higher than in ACPA-positive RA (25.0% vs. 29,6%, p=0.019, chi2 test). The disease duration did not differ between in PRGNabs negative or positive RA patients (8.1 vs. 7.9 years). <h3>Conclusions</h3> PGRNabs are positive in more than 30% of sera of RA patients who are seronegative for RF-IgM and ACPA. These results suggest that testing for PRGNabs can reduce the seronegative status in RA patients. However, the data has to be confirmed by a larger validation cohort of RF and ACPA negative RA patients. <h3>References</h3> Thurner L, Zaks M, Preuss KD, Fadle N, Regitz E, Ong MF, Pfreundschuh M, Assmann G. Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis. Arthritis Res Ther. 2013;15(6):R211. <h3>Disclosure of Interest</h3> None declared
THU0324 Obesity Interferes with The Inflammatory Status in Lupus Patients
Authors: F.M.M. Santos, J.C. Lino, K.C. Correia, R. Reis, M.V. Andrade, R.W. Telles, M.I. Correia, C.C. Lanna
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> High frequency of obesity among SLE patients has been described, however, it is unknown whether obesity can modify the inflammatory status of those individuals. <h3>Objectives</h3> To analyze the profile of cytokines and evaluate whether obesity interferes with the inflammatory status of SLE patients. <h3>Methods</h3> Cross-sectional study included 189 women with SLE and 70 controls, older than 18 years, were included in the study. Data related to clinical and laboratory manifestations besides medication use were assessed. Disease activity was measured by SLEDAI-2K and irreversible cumulative damage by SLICC-ACR/DI. Nutritional status was assessed by body mass index (BMI). Serum concentrations of IL6, IL10, IL17, TNFα, soluble TNFα receptors 1 (sTNFR1) and 2 (sTNFR2) were analyzed using high sensitivity cytometric bead array and adipokines (leptin and adiponectin) by ELISA kits. Multiple linear regression method was performed for multivariate analysis. In order to adjust the multivariate models the following variables were included: age, menopause, disease activity, use of antimalarial drugs, immunosuppressive and current dose of corticosteroids. <h3>Results</h3> In lupus patients group, mean (SD) values of age and disease duration were, respectively, 37.5 (10.0) and 9.1 (6.3) years. Considering BMI, 72 (38.1%) patients were classified as eutrophic, 64 (33.9%) as overweight and 53 (28.0%) as obese. The mean (SD) cumulative dose of prednisone was 32.9 (26.1) g, and of the current daily dose of prednisone was 10.4 (12.9) mg. The median (IQR) disease activity and damage index scores were 2 (0–6) and 0 (0–1), respectively. Serum levels of cytokines were higher in lupus patients when compared to controls [IL6 (p&lt;0.001), sTNFR1 (p=0.028), sTNFR2 (p=0.003), IL10 (p&lt;0.001), leptin (p=0.044) and adiponectin (p&lt;0.001)]. Only the IL17 levels (p=0.518) did not differ statistically between the two groups. Higher BMI correlated with age (rs =0.335; p = &lt;0.001), age at diagnosis (rs=0.319; p≤0.001) and with less years of education (rs= -0.204; p=0.005). No correlation was observed between BMI and disease activity (rs: 0.116 p=0.113) as well as with damage index (rs:-0.080 p=0.309). Higher concentrations of IL6 (rs=0.246, p=0.002), IL17 (rs=0.195, p=0.014) and leptin (rs=0.430; p&lt;0.001) were positively and independently correlated with BMI. <h3>Conclusions</h3> This study showed higher serum levels of cytokines and adipokines in SLE patients. Also, higher BMI was correlated with higher concentrations of IL6, IL17 and leptin in the study group, suggesting that BMI could interfere, regardless of disease activity, with the inflammatory profile of women with SLE. <h3>Disclosure of Interest</h3> None declared
SP0174 Health Behaviour Change Techniques To Effectively Promote Physical Activity in People with Rheumatoid Arthritis
Authors: K. Knittle
Journal: Annals of the Rheumatic Diseases (2016)

Engaging in sufficient levels of physical activity (PA) is of particular importance for patients with rheumatoid arthritis (RA), as it can help to maintain functional ability and reduce the risk of cardiovascular disease. While many healthcare professionals have the ability to effectively promote PA among patients with RA, some techniques common in clinical practice can actually be counterproductive. As consultations are becoming increasingly shorter, having a clear understanding of the evidence on how to best promote PA in practice can help healthcare providers9 to improve the efficiency and effectiveness of their PA promotion efforts. This session will provide an overview of prominent behavioural determinants and theories, and outline how behaviour change typically unfolds among patients with rheumatoid arthritis. It will then present research which has identified behaviour change techniques associated with increased motivation and intention for PA and changes in PA behaviour itself. Finally, it will provide practical, evidence-based tips that can be implemented to help guide behaviour and lifestyle change efforts in clinical settings, even when time is short. <h3>Disclosure of Interest</h3> None declared
Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer
Authors: Maximilian Koch, Johannes S. de Jong, Jürgen Glatz, Panagiotis Symvoulidis, Laetitia E. Lamberts, Arthur L.L. Adams, Mariëtte E.G. Kranendonk, Anton G.T. Terwisscha van Scheltinga, Michaela Aichler, Liesbeth Jansen, Jakob de Vries, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Annelies Jorritsma-Smit, Matthijs D. Linssen, Esther de Boer, Bert van der Vegt, Wouter B. Nagengast, Sjoerd G. Elias, Sabrina Oliveira, Arjen J. Witkamp, Willem P.T.M. Mali, Elsken Van der Wall, P. Beatriz Garcia-Allende, Paul J. van Diest, Elisabeth G.E. de Vries, Axel Walch, Gooitzen M. van Dam, Vasilis Ntziachristos
Journal: Cancer Research (2016)

In vivo tumor labeling with fluorescent agents may assist endoscopic and surgical guidance for cancer therapy as well as create opportunities to directly observe cancer biology in patients. However, malignant and nonmalignant tissues are usually distinguished on fluorescence images by applying empirically determined fluorescence intensity thresholds. Here, we report the development of fSTREAM, a set of analytic methods designed to streamline the analysis of surgically excised breast tissues by collecting and statistically processing hybrid multiscale fluorescence, color, and histology readouts toward precision fluorescence imaging. fSTREAM addresses core questions of how to relate fluorescence intensity to tumor tissue and how to quantitatively assign a normalized threshold that sufficiently differentiates tumor tissue from healthy tissue. Using fSTREAM we assessed human breast tumors stained in vivo with fluorescent bevacizumab at microdose levels. Showing that detection of such levels is achievable, we validated fSTREAM for high-resolution mapping of the spatial pattern of labeled antibody and its relation to the underlying cancer pathophysiology and tumor border on a per patient basis. We demonstrated a 98% sensitivity and 79% specificity when using labeled bevacizumab to outline the tumor mass. Overall, our results illustrate a quantitative approach to relate fluorescence signals to malignant tissues and improve the theranostic application of fluorescence molecular imaging. Cancer Res; 77(3); 623-31. ©2016 AACR.
Outcomes of Allogeneic Hematopoietic Cell Transplantation In Aplastic Anemia Using Intermediate Dose Alemtuzumab Based-Conditioning
Authors: Nada Hamad, Ryan Del Bel, Hans A. Messner, Dennis Kim, John Kuruvilla, Jeffrey H. Lipton, Jieun Uhm, Wei Xu, Vikas Gupta
Journal: Blood (2013)
B Cell Immune Profiles in Essential Thrombocythemia with Calr Mutations: Clinical and Molecular Correlates
Authors: Yu-Cheng Chang, Ken-Hong Lim, Huan-Chau Lin, Yi-Hao Chiang, Ling Huang, Chen-Wei Kao, Chiao-Yi Chang, Ching-Sung Lin, Nai-Wen Su, Johnson Lin, Ruey-Kuen Hsieh, Ming-Chih Chang, Yi-Fang Chang, Caleb Gon-Shen Chen, Yuan-Yeh Kuo, Wen-Chien Chou
Journal: Blood (2015)
Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study
Authors: Daniel W. Lin, Lisa F. Newcomb, Marshall D. Brown, Daniel D. Sjoberg, Yan Dong, James D. Brooks, Peter R. Carroll, Matthew Cooperberg, Atreya Dash, William J. Ellis, Michael Fabrizio, Martin E. Gleave, Todd M. Morgan, Peter S. Nelson, Ian M. Thompson, Andrew A. Wagner, Yingye Zheng
Journal: European Urology (2016)
In CML Patients with Good Response to TKIs Other Gene Mutations Are Frequently (37%) Present in Addition to Philadelphia Negative, Cytogenetically Aberrant Clones but Are Rare (4%) in Cases with MMR and Normal Karyotype
Authors: Susanne Schnittger, Manja Meggendorfer, Niroshan Nadarajah, Tamara Alpermann, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach
Journal: Blood (2014)
PWE-054 Does Double Balloon Enteroscopy Have A Role In The Young with Iron Deficiency Anaemia? A Multicentre European Study
Authors: H-L Ching, F Branchi, DE Yung, A Koulaouzidis, J Plevris, L Elli, DS Sanders, R Sidhu
Journal: Gut (2016)

<h3>Introduction</h3> Double balloon endoscopy (DBE) has been reported to have a high diagnostic yield in obscure overt gastrointestinal bleeding (OGB). There is paucity of studies of DBE for the indication of iron deficiency anaemia (IDA) alone particularly in the young. We investigated the utility of DBE in patients referred with IDA according to age. <h3>Methods</h3> All consecutive patients undergoing DBE for IDA and OGB, between June 2006 and January 2016, across 3 teaching hospitals in the UK and Italy were included in the study. Demographic and clinical data were collected and patients were categorised by age (≥55 and &lt;55 years) and those undergoing DBE for IDA or OGB. Diagnostic and therapeutic yields as well as complication rates were determined and compared. A secondary comparison was made between patients with IDA and overt bleeding in similar age groups. <h3>Results</h3> 213 patients underwent DBE for IDA. 142 (66.7%) were age ≥ 55 years (mean age 69.6±8.6, 49.3% male) and 71 (33.3%) age &lt;55 years (mean age 42.7±9.2, 66.2% male). The most common pathologies found at DBE (≥55 vs &lt;55 years) were angioectasias (45.1% vs 18.3%, <b>p &lt; 0.05</b>), tumours (4.9% vs 5.6%, p = 1), and ulcers (4.9% vs 8.5%, p = 0.37). Diagnostic yield was higher in those aged ≥55 years (≥55 vs &lt;55 years; 64.1% vs 39.4%, <b>p &lt; 0.05</b>). Therapeutic yield and complication rates on the other hand were comparable across both groups (30.3% vs 21.1%, p = 0.19 and 2.1% vs 4.2% p = 0.40 respectively). Further comparisons between young patients aged &lt;55 years with IDA and those in the same age group with OGB (n = 23, mean age 43.5±8.8, 47.8% male) revealed similar frequencies of angioectasias (18.3% vs 13%, p = 0.75), tumours (5.6% vs 8.7%, p = 0.63) and ulcers (8.5% vs 0%, p = 0.33). There was no difference in the rate of positive capsule endoscopy findings preceding DBE between the two groups (59.2% vs 47.8%, p = 0.47). Diagnostic yield (39.4% vs 47.8%, p = 0.63) and therapeutic yield (21.1% vs 17.4%, p = 1) were also comparable while the difference in complication rates did not reach statistical significance (4.2% vs 0%, p = 1) between young IDA and OGB patients. <h3>Conclusion</h3> We present the first multicentre study evidencing the safety and high diagnostic yield of DBE in patients with IDA. Although the diagnostic yield is lower in the young, significant pathology is detected including tumours and ulceration, supporting the role of DBE in young patients with IDA. <h3>Disclosure of Interest</h3> None Declared